IR Searcher

基本データ

【業種】: 医薬品
【市場】: プライム（内国株式）
【決算期】: 2月
【会社設立】
【上場】: 1962.9
【直近決算日】: 2025-07-10（1Q）
【決算予定日】: 未定

【時価総額】: 3352億0900万円
【PBR】: 1.05倍
【配当利回り(予)】: 3.05%

企業概要

同社は主に医薬品事業を中心に展開している企業グループであり、連結子会社19社や関連会社を通じて多様な製品を製造販売している。
主力製品には、経皮鎮痛消炎剤の「モーラステープ」やがん疼痛治療剤の「フェントステープ」、一般用医薬品の「サロンパス」などが含まれ、特に外用剤市場において強い競争力を持つ。
海外においても、アメリカをはじめとした地域での展開を行い、商品の供給や製品開発においては地元企業との協力を図りながら成長を目指す体制が整っている。
また、医療用及び一般用医薬品の領域での幅広い疾患に対応する製品開発も推進している。

業績修正履歴

年度	タイプ	日付	売上高	営業利益	経常利益	純利益
2023-02	新規	2022-04-07	123,000	11,100	12,700	9,700
	変更	2023-03-30	128,300(⬆)	11,500(⬆)	16,000(⬆)	12,000(⬆)
2024-02	新規	2023-04-13	132,300	11,800	14,600	10,600
	変更	2024-01-11	141,000(⬆)	14,400(⬆)	19,900(⬆)	14,600(⬆)
2025-02	新規	2024-04-11	152,000	14,500	18,900	15,800
	変更	2025-01-09	154,000(⬆)	18,000(⬆)	23,000(⬆)	20,500(⬆)
今期	新規	2025-04-10	165,000	20,000	24,300	22,000

通期四半期別

売上高

経常利益

純利益

通期四半期別

決算期	四半期	売上高	営業利益	経常利益	純利益	1株当たり純利益	営業利益率	経常利益率	売上高/前年比	営業利益/前年比	経常利益/前年比	純利益/前年比
	予想	165,000	20,000	24,300	22,000	298.86	12.12%	14.73%	5.77%	5.85%	1.21%	1.11%
2026-02	1	34,665	3,364	3,780	2,564	35.14	9.7%	10.9%	-3.2%	-18.9%	-32%	-46.4%
2025-02	4	156,006	18,895	24,010	21,758	295.57	12.11%	15.39%	10.1%	43.5%	22.2%	55.8%
	3	111,253	13,220	16,471	13,660	185.02	11.88%	14.8%	8.2%	8%	-1%	13%
	2	75,456	9,006	10,788	9,098	122.71	11.94%	14.3%	12.7%	7.3%	-7.3%	8.1%
	1	35,810	4,149	5,562	4,788	63.89	11.59%	15.53%	11.6%	-4.9%	-2.7%	18.2%
2024-02	4	141,706	13,167	19,649	13,969	181.62	9.29%	13.87%	10.4%	13.5%	22.4%	19%
	3	102,827	12,270	16,661	12,110	156.64	11.93%	16.2%	11.9%	44.2%	28.1%	27.2%
	2	66,977	8,396	11,640	8,417	108.34	12.54%	17.38%	12.3%	70.9%	31.2%	29.4%
	1	32,096	4,361	5,713	4,049	52.09	13.59%	17.8%	21.6%	739.1%	148.6%	148.2%
2023-02	4	128,330	11,599	16,051	11,742	148.01	9.04%	12.51%	6.8%	24.2%	27%	21.6%
	3	91,881	8,506	13,003	9,522	119.46	9.26%	14.15%	6%	22%	50.1%	53.1%
	2	59,619	4,913	8,870	6,504	81.58	8.24%	14.88%	1.8%	-13.9%	29.7%	30%
	1	26,393	519	2,298	1,631	20.46	1.97%	8.71%	-4.9%	-75.5%	-19.5%	-30.9%
2022-02	4	120,193	9,337	12,638	9,658	118.92	7.77%	10.51%	5%	-12.5%	6.8%	4.4%
	3	86,663	6,973	8,665	6,218	76.14	8.05%	10%	7.2%	-14.2%	9.3%	8.7%
	2	58,551	5,706	6,836	5,002	61.2	9.75%	11.68%	10.6%	3.5%	23.9%	35.4%
	1	27,761	2,120	2,855	2,362	28.91	7.64%	10.28%	11.6%	96.6%	582.9%	1979.9%
2021-02	4	114,510	10,671	11,829	9,250	113.22	9.32%	10.33%	-18.8%	-53%	-53.8%	-50.5%
	3	80,822	8,123	7,928	5,722	70.04	10.05%	9.81%	-18.4%	-55.9%	-60.2%	-62.9%
	2	52,926	5,516	5,519	3,693	45.22	10.42%	10.43%	-16.5%	-45.9%	-48.1%	-51.1%
	1	24,882	1,078	418	113	1.39	4.33%	1.68%	-14.9%	-61.2%	-85.4%	-94.1%
2020-02	4	140,992	22,727	25,628	18,694	227.58	16.12%	18.18%	-1.7%	2%	4%	-2.7%
	3	99,078	18,417	19,917	15,420	187.36	18.59%	20.1%	-3.4%	15.4%	14.4%	15.7%
	2	63,401	10,190	10,641	7,548	91.37	16.07%	16.78%	-8.6%	-9.4%	-11.4%	-17.6%
	1	29,233	2,778	2,863	1,913	23.15	9.5%	9.79%	-12.8%	-36.3%	-35.6%	-44.6%
2019-02	4	143,408	22,278	24,647	19,204	230.08	15.53%	17.19%	-3.4%	-17.3%	-12.7%	0.4%
	3	102,574	15,941	17,412	13,329	159.35	15.54%	16.98%	-6.4%	-22.9%	-21%	-15.8%
	2	69,384	11,229	12,012	9,158	109.46	16.18%	17.31%	-5.6%	-11.1%	-6.7%	-2.4%
	1	33,499	4,354	4,449	3,452	41.27	13%	13.28%	-7.2%	-14.4%	-10%	-6%
2018-02	4	147,870	26,345	28,245	19,119	228.52	17.82%	19.1%	1.3%	0.2%	0.2%	-6.3%
	3	109,553	20,687	22,043	15,840	189.33	18.88%	20.12%	-0.2%	-5.9%	-3.7%	-13.6%
	2	73,463	12,629	12,869	9,386	112.19	17.19%	17.52%	-1.3%	-1.9%	2.5%	1.1%
	1	36,081	5,090	4,941	3,674	43.92	14.11%	13.69%	-5.4%	-11.4%	-11.2%	-18.9%
2017-02	4	145,925	26,306	28,179	20,395	241.27	18.03%	19.31%	-9.8%	-5.1%	0.6%	14.7%
	3	109,729	21,995	22,885	18,340	216.23	20.04%	20.86%	-10.3%	-5.7%	-2.5%	19.7%
	2	74,447	12,875	12,554	9,286	109.47	17.29%	16.86%	-9.7%	-11.3%	-14.1%	-1%
	1	38,153	5,744	5,561	4,529	53.5	15.06%	14.58%	-3.8%	0.1%	-1.8%	28.1%

決算期	四半期	売上高	営業利益	経常利益	純利益	1株当たり純利益	営業利益率	経常利益率	売上高/前年比	営業利益/前年比	経常利益/前年比	純利益/前年比
2026-02	1	34,665	3,364	3,780	2,564	35.14	9.7%	10.9%	-3.2%	-18.9%	-32%	-46.4%
2025-02	4	44,753	5,675	7,539	8,098	110.55	12.68%	16.85%	15.11%	532.66%	152.31%	335.61%
	3	35,797	4,214	5,683	4,562	62.31	11.77%	15.88%	-0.15%	8.78%	13.18%	23.53%
	2	39,646	4,857	5,226	4,310	58.82	12.25%	13.18%	13.66%	20.37%	-11.83%	-1.33%
	1	35,810	4,149	5,562	4,788	63.89	11.59%	15.53%	11.6%	-4.9%	-2.7%	18.2%
2024-02	4	38,879	897	2,988	1,859	24.98	2.31%	7.69%	6.67%	-71%	-1.97%	-16.26%
	3	35,850	3,874	5,021	3,693	48.3	10.81%	14.01%	11.12%	7.82%	21.49%	22.37%
	2	34,881	4,035	5,927	4,368	56.25	11.57%	16.99%	4.98%	-8.17%	-9.81%	-10.36%
	1	32,096	4,361	5,713	4,049	52.09	13.59%	17.8%	21.6%	739.1%	148.6%	148.2%
2023-02	4	36,449	3,093	3,048	2,220	28.55	8.49%	8.36%	8.71%	30.84%	-23.28%	-35.47%
	3	32,262	3,593	4,133	3,018	37.88	11.14%	12.81%	14.76%	183.58%	125.97%	148.19%
	2	33,226	4,394	6,572	4,873	61.12	13.22%	19.78%	7.91%	22.53%	65.08%	84.58%
	1	26,393	519	2,298	1,631	20.46	1.97%	8.71%	-4.9%	-75.5%	-19.5%	-30.9%
2022-02	4	33,530	2,364	3,973	3,440	42.78	7.05%	11.85%	-0.47%	-7.22%	1.85%	-2.49%
	3	28,112	1,267	1,829	1,216	14.94	4.51%	6.51%	0.77%	-51.4%	-24.08%	-40.07%
	2	30,790	3,586	3,981	2,640	32.29	11.65%	12.93%	9.79%	-19.2%	-21.96%	-26.26%
	1	27,761	2,120	2,855	2,362	28.91	7.64%	10.28%	11.6%	96.6%	582.9%	1979.9%
2021-02	4	33,688	2,548	3,901	3,528	43.18	7.56%	11.58%	-19.63%	-40.88%	-31.69%	7.76%
	3	27,896	2,607	2,409	2,029	24.82	9.35%	8.64%	-21.81%	-68.31%	-74.03%	-74.23%
	2	28,044	4,438	5,101	3,580	43.83	15.83%	18.19%	-17.92%	-40.12%	-34.42%	-36.47%
	1	24,882	1,078	418	113	1.39	4.33%	1.68%	-14.9%	-61.2%	-85.4%	-94.1%
2020-02	4	41,914	4,310	5,711	3,274	40.22	10.28%	13.63%	2.64%	-31.99%	-21.06%	-44.27%
	3	35,677	8,227	9,276	7,872	95.99	23.06%	26%	7.49%	74.6%	71.78%	88.73%
	2	34,168	7,412	7,778	5,635	68.22	21.69%	22.76%	-4.78%	7.81%	2.84%	-1.24%
	1	29,233	2,778	2,863	1,913	23.15	9.5%	9.79%	-12.8%	-36.3%	-35.6%	-44.6%
2019-02	4	40,834	6,337	7,235	5,875	70.73	15.52%	17.72%	6.57%	12%	16.66%	79.17%
	3	33,190	4,712	5,400	4,171	49.89	14.2%	16.27%	-8.04%	-41.52%	-41.14%	-35.37%
	2	35,885	6,875	7,563	5,706	68.19	19.16%	21.08%	-4%	-8.81%	-4.6%	-0.11%
	1	33,499	4,354	4,449	3,452	41.27	13%	13.28%	-7.2%	-14.4%	-10%	-6%
2018-02	4	38,317	5,658	6,202	3,279	39.19	14.77%	16.19%	5.86%	31.25%	17.15%	59.56%
	3	36,090	8,058	9,174	6,454	77.14	22.33%	25.42%	2.29%	-11.64%	-11.2%	-28.72%
	2	37,382	7,539	7,928	5,712	68.27	20.17%	21.21%	3%	5.72%	13.37%	20.08%
	1	36,081	5,090	4,941	3,674	43.92	14.11%	13.69%	-5.4%	-11.4%	-11.2%	-18.9%
2017-02	4	36,196	4,311	5,294	2,055	25.04	11.91%	14.63%	-8.52%	-2.16%	16.58%	-16.67%
	3	35,282	9,120	10,331	9,054	106.76	25.85%	29.28%	-11.47%	3.46%	16.8%	52.37%
	2	36,294	7,131	6,993	4,757	55.97	19.65%	19.27%	-15.1%	-18.71%	-21.94%	-18.56%
	1	38,153	5,744	5,561	4,529	53.5	15.06%	14.58%	-3.8%	0.1%	-1.8%	28.1%

4530 久光製薬 企業サイト Yahooファイナンス 日経新聞 株探 四季報

4530 久光製薬　企業サイト　　　Yahooファイナンス　日経新聞　株探　四季報　